Lupin's Pithampur Unit 1 receives Establishment Inspection Report

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the U.S. FDA between 03 February 2020 and 11 February 2020 and concluded with two observations.

Powered by Capital Market - Live News